ZGNX - Zogenix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
49.00
+1.95 (+4.14%)
As of 12:35PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close47.05
Open47.10
Bid48.75 x 800
Ask48.85 x 1100
Day's Range47.00 - 49.80
52 Week Range11.80 - 62.75
Volume318,429
Avg. Volume795,203
Market Cap2.05B
Beta1.92
PE Ratio (TTM)N/A
EPS (TTM)-4.37
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est78.60
Trade prices are not sourced from all markets
  • Benzinga6 days ago

    Zogenix Has $3.4B Opportunity With Pediatric Epilepsy Asset, BofA Says In Bullish Initiation

    Zogenix, Inc. (NASDAQ: ZGNX )'s lead asset ZX008 presents a multibillion-dollar opportunity, according to Bank of America Merrill Lynch. The Analyst Analyst Tazeen Ahmad initiated coverage of Zogenix with ...

  • Investors in This Top Marijuana Stock Can't Overlook These 2 Serious Challenges
    Motley Fool7 days ago

    Investors in This Top Marijuana Stock Can't Overlook These 2 Serious Challenges

    Though this pot stock has been unstoppable for years, things may not stay that way for much longer.

  • TheStreet.com10 days ago

    Six Biotechnology Names on My Watch List

    The indices have been slowly drifting lower after a gap up open. Early breadth was around 3 to 1 positive but its now down to around 4-3 positive. The bulls are not producing much positive momentum but the bears are doing an even worse job of producing negative momentum.

  • Here's Why Zogenix Slipped 14.9% in August
    Motley Fool10 days ago

    Here's Why Zogenix Slipped 14.9% in August

    The company announced and completed a share offering last month, but the timing worked out well.

  • TheStreet.com12 days ago

    Don't Dread a Market Correction, Think Opportunistically Instead

    Market corrections are too often feared by market players rather than embraced. The problem is that optimism tends to erode when there is a poor market and we are dealing with losses in individual stocks.

  • GlobeNewswire16 days ago

    Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to four new non-executive employees. The awards were made on September 1, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company.  The inducement awards consist of options to purchase an aggregate of 22,400 shares of Zogenix common stock.  The options have a ten-year term and an exercise price equal to $48.30, the fair market value of Zogenix common stock on the date of grant.  The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter.

  • ACCESSWIRE16 days ago

    Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Zogenix

    NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Major U.S. equities closed mostly higher on Friday and posted upbeat performance for the week. Market volatility source have been coming from U.S. and international ...

  • GlobeNewswire16 days ago

    Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that detailed results of the Phase 2, open-label study evaluating its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of refractory patients with Lennox-Gastaut Syndrome (LGS), were published in the September 2018 issue of Epilepsia. Consistent with the previously-reported data from this study, the results demonstrated that ZX008 provided sustained, clinically meaningful seizure reduction in the majority of patients and was generally well-tolerated.

  • GlobeNewswire21 days ago

    Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced new findings from multiple studies assessing the psychological and socioeconomic impact of epileptic encephalopathies, such as Dravet syndrome, in the United States and Europe. The first analysis found that siblings of children with epileptic encephalopathies may be at risk for anxiety or depression, with a significant proportion of both younger siblings and adult siblings reporting symptoms of anxiety and depressed mood.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Mallinckrodt Public and Zogenix

    NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ZGNX earnings conference call or presentation 6-Aug-18 8:30pm GMT

    Q2 2018 Zogenix Inc Earnings Call

  • GlobeNewswirelast month

    Zogenix Prices Public Offering of Common Stock

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $52.00 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering costs, are expected to be $312,000,000.  Zogenix has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares to be sold in the offering are being sold by Zogenix.

  • Associated Presslast month

    Zogenix: 2Q Earnings Snapshot

    The Emeryville, California-based company said it had a loss of 83 cents per share. Losses, adjusted to account for discontinued operations, were 82 cents per share. The results beat Wall Street expectations. ...

  • GlobeNewswirelast month

    Zogenix Announces Proposed Public Offering of 6,000,000 Shares of Common Stock

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it intends to offer and sell, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering. Zogenix also expects to grant to the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares to be sold in the offering are to be sold by Zogenix.

  • GlobeNewswirelast month

    Zogenix Provides Corporate Update and Reports Second Quarter Financial Results

    Reported positive top-line results from second pivotal Phase 3 trial of ZX008 in patients with Dravet syndrome, Study 1504 Submission of U.S. and EU regulatory filings for ZX008 in Dravet syndrome anticipated ...

  • ACCESSWIRElast month

    Zogenix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Zogenix, Inc. (NASDAQ: ZGNX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To listen ...

  • GlobeNewswire2 months ago

    Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    The awards were made on August 1, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company.  The inducement awards consist of options to purchase an aggregate of 32,000 shares of Zogenix common stock.  The options have a ten-year term and an exercise price equal to $56.20, the fair market value of Zogenix common stock on the date of grant.  The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • GlobeNewswire2 months ago

    Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6

    EMERYVILLE, Calif., Aug. 01, 2018-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of rare central nervous system disorders, today announced that it will report its financial ...

  • Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks
    MarketWatch2 months ago

    Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks

    Valuations today are very high and sentiment is very positive — a bad combination, says Nigam Arora.

  • 3 Very Popular Marijuana Stocks on My "Do Not Buy" List
    Motley Fool2 months ago

    3 Very Popular Marijuana Stocks on My "Do Not Buy" List

    Not all pot stocks will have investors seeing green.

  • Motley Fool2 months ago

    Is Marijuana the Best Medicine for Epilepsy?

    A new marijuana-based drug will soon be available for some epilepsy patients, but another drug might work even better.

  • Motley Fool2 months ago

    These Epilepsy Drugmakers Are About to Brawl

    A new spin on an old drug could dent demand for Epidiolex, a marijuana-based epilepsy drug. Plus, here's how important Medicare and Medicaid are to UnitedHealth Group's profits.

  • 3 Big-Name Marijuana Stocks With Plunging Profit Projections
    Motley Fool2 months ago

    3 Big-Name Marijuana Stocks With Plunging Profit Projections

    Investors may not see as much green with these pot stocks as once expected.

  • ACCESSWIRE2 months ago

    The Market That Took BEAT Higher By 800% Could Do The Same For This Strong New Competitor

    Cardiac monitoring is a $32 billion market, and the companies that are successfully navigating this space with new technology are seeing huge returns: IRTC is up 300% in 3 years, and BEAT up 800% in 5 years. Biotricity (BTCY) is the most recent entrant into the remote monitoring space with their first FDA clearance in December. The launch of Bioflux, an advanced remote ECG monitoring device, is underway and first sales should emerge in the coming months after having signed some respected anchor clients.

  • ACCESSWIRE2 months ago

    Free Pre-Market Technical Recap on TherapeuticsMD and Three Additional Healthcare Stocks

    LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on TXMD sign up now at www.wallstequities.com/registration. On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE AMER: PTN), TherapeuticsMD Inc. (NASDAQ: TXMD), and Zogenix Inc. (NASDAQ: ZGNX).